Supplementary Materials

Supplementary Material for:

Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease

Michael M. Lipp, Richard Batycky, Jerome Moore, Mika Leinonen, Martin I. Freed*

*Corresponding author. Email: mlipp{at}acorda.com

Published 12 October 2016, Sci. Transl. Med. 8, 360ra136 (2016)
DOI: 10.1126/scitranslmed.aad8858

This PDF file includes:

  • Table S1. Pharmacokinetic findings after single-dose levodopa insufflation or oral levodopa administration to dogs.
  • Table S2. Levodopa pharmacokinetics at early time points after single-dose CVT-301 inhalation or oral levodopa ingestion by healthy volunteers.
  • Table S3. Key levodopa pharmacokinetic parameters estimated by noncompartmental analysis after single-dose CVT-301 inhalation or oral levodopa ingestion by healthy volunteers.
  • Table S4. Percent coefficients of variability (%CV) for plasma levodopa concentrations after single-dose CVT-301 inhalation or oral levodopa ingestion by healthy volunteers.
  • Table S5. Levodopa pharmacokinetics after single-dose CVT-301 inhalation or oral levodopa ingestion by PD patients during an OFF episode—baseline-adjusted values.
  • Table S6. Percent coefficients of variability (%CV) for baseline-adjusted incremental plasma levodopa concentrations after CVT-301 inhalation or oral levodopa ingestion by PD patients during an OFF episode.
  • Table S7. Cough as a reported AE after study-drug inhalation by PD patients during an OFF state.
  • Table S8. Summary of patients’ baseline characteristics in the phase 2 study.

[Download PDF]